IPO Filing Floodgates: Aegerion Pharmaceuticals, Inc. (AEGR)

Aegerion Pharmaceuticals, Inc. filed Tuesday for an initial public offering of up to $86.25 million in securities for filing purposes.  It has the proposed ticker of "AEGR" on NASDAQ, and the underwriting group consists of Piper Jaffray, Thomas Weisel partners, Lazard Capital Markets, and Collins Stewart, LLC. 

Aegerion is an emerging biotech company focused on small-molecule therapeutics to treat cardiovascular and metabolic disease.  Its lead product candidates, AEGR-733 and AEGR-427, are microsomal triglyceride transfer protein inhibitors, or MTP-Is, which limit secretion of cholesterol and triglycerides from both the intestine and liver.

24/7 Wall St. will have to do some research here because this IPO had originally been filed back in March 2007, but was withdrawn from registration in June.

If you wish to join our open email distribution list we often provide more detailed IPO and spin-off coverage.  These are frequently lead-ins to our subscriber-based "Special Situation Investing Newsletter" where we cover buyouts, spin-offs, back-door plays into IPO’s, reorganizations, and more.

Jon C. Ogg
November 21, 2007